Drugmaker Eli Lilly and Company will be moving forward with a third set of clinical trials to seek a drug that would delay the progression of mild to moderate Alzheimer’s Disease.  Learn more in this article from Inside Elder Care.

The Indianapolis company will begin enrolling patients this month in two separate but identical Phase III clinical trials of Solanezumab, an antibody that may hold the key to preventing the disease that affects 5.3 million people in the United States alone.

Click here for full article: